Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01853553 · ClinicalTrials.gov registry record · Phase 3
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 3 study of ADPKD, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT01853553: Completed Phase 3 study of ADPKD, sponsored by University of Colorado, Denver.
NCT01853553 is a Phase 3 study of ADPKD that has completed, run by University of Colorado, Denver. The registered enrollment target is 61 participants, below the 225-participant average among 3 other ADPKD trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01853553, a Phase 3 study of ADPKD, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed research will determine the effectiveness of blocking aldosterone for improving the health and function of arteries in patients with autosomal dominant polycystic kidney disease (ADPKD). The study also will provide insight into how blocking aldosterone improves artery health by determining the physiological mechanisms (biological reasons) involved. Overall, the proposed research will provide important new scientific evidence upon which physicians can base recommendations to patients with ADPKD to decrease risk of developing cardiovascular diseases.
Primary Outcome
FMD will be determined using high-resolution ultrasonography
Conditions Studied
Interventions
- DRUG Spironolactone
- DRUG Sugar pill
Study Locations (1)
Colorado
- UColorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
What the finished NCT01853553 record still lists
NCT01853553 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 225-participant average among 3 other ADPKD trials with a reported enrollment target (73% lower).
The record links to 1 condition, with ADPKD appearing as the primary indexed condition, and to 2 interventions - of which Spironolactone is the first listed.
NCT01853553 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT01853553 about?
NCT01853553 is a clinical study titled "Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)". The proposed research will determine the effectiveness of blocking aldosterone for improving the health and function of arteries in patients with autosomal dominant polycystic kidney disease (ADPKD). The study also will provide insight into how blocking aldosterone improves artery health by determin...
What is the current status of trial NCT01853553?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2013-07. Estimated completion is 2017-01.
What conditions does trial NCT01853553 study?
This clinical trial studies the following conditions: ADPKD.
What interventions are being tested in trial NCT01853553?
The interventions under investigation include: Spironolactone (DRUG), Sugar pill (DRUG).
Who is sponsoring clinical trial NCT01853553?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01853553 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADPKD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia